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Type 2 diabetes (T2D) and Alzheimer disease (AD) are two major health issues nowadays.
T2D is an ever increasing epidemic, affecting millions of elderly people worldwide, with
major repercussions in the patients’ daily life. This is mostly due to its chronic complica-
tions that may affect brain and constitutes a risk factor for AD. T2D principal hallmark is
insulin resistance which also occurs in AD, rendering both pathologies more than mere
unrelated diseases. This hypothesis has been reinforced in the recent years, with a high
number of studies highlighting the existence of several common molecular links. As such, it
is not surprising that AD has been considered as the “type 3 diabetes” or a “brain-specific
T2D,” supporting the idea that a beneficial therapeutic strategy against T2D might be also
beneficial against AD. Herewith, we aim to review some of the recent developments on
the common features between T2D and AD, namely on insulin signaling and its participa-
tion in the regulation of amyloid β (Aβ) plaque and neurofibrillary tangle formation (the two
major neuropathological hallmarks of AD). We also critically analyze the promising field that
some anti-T2D drugs may protect against dementia and AD, with a special emphasis on
the novel incretin/glucagon-like peptide-1 receptor agonists.
Keywords: Alzheimer disease, anti-type 2 diabetes compounds, brain, exendin-4, incretins/glucagon-like peptide-
1/glucagon-like peptide-1 receptor, insulin/insulin receptor signaling, type 2 diabetes
INTRODUCTION
Given its ever increasing number of patients worldwide, diabetes
mellitus (DM) is a modern epidemic and a highly concerning
global health care issue, with recent estimates pointing to an
increase from 285 to 439 million patients from 2010 to 2030
(1). Despite the several types of diabetes existent, type 2 diabetes
(T2D) constitutes an unquestionable major public health threat,
accounting for more than 90% of all cases (1, 2). T2D-related
socio-economic concern is also due to the burden constituted by
its highly common, morbid, and mortal long-term complications
affecting several tissues and organs, including the central nervous
system (CNS) (3). Although traditionally, T2D used to occur in
people aged above 30 years, nowadays its incidence is also increas-
ing among younger people (4), probably due to other risk factors
(besides aging) associated with modern lifestyle. These include
high blood pressure, sedentarism, and metabolic syndrome, the
later constituting a group of disorders (e.g., dyslipidemia and
obesity) related to a high risk for cardiovascular disease (1, 5, 6).
Type 2 diabetes is characterized by abnormally high blood glu-
cose levels (hyperglycemia) due to insulin resistance that may
progress toward pancreatic β-cell dysfunction and a generalized
loss of insulin sensitivity in the later stages of disease (7). Chronic
T2D is known to negatively affect the CNS structure and function,
ultimately constituting a known risk factor for dementia [both
vascular dementia and Alzheimer disease (AD)] (8). Although the
precise mechanisms underlying neurodegeneration and impaired
cognition in T2D remain poorly understood, it has been hypothe-
sized that insulin resistance (impaired insulin signaling) may play
a critical role, particularly in the elderly (9, 10). This is not sur-
prising, giving that aging is a well-known common risk factor to
both T2D and AD (11) and recent hypotheses suggest that AD
might be a neuroendocrine-like disorder, a so-called “type 3 dia-
betes” (12, 13) or a “brain-specific T2D” (14). Accordingly, Janson
et al. reported that both T2D and impaired fasting glucose were
more prevalent in AD than in non-AD individuals from the Mayo
Clinic Alzheimer Disease Patient Registry, with 81% of AD patients
exhibiting either T2D or impaired fasting glucose (15).
Considering the close correlation between T2D and AD, it has
been generally accepted that an accurate and early diagnosis of
T2D, a provision of durable glycemic control and, at least in the
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initial phases of the disease, a convenient prevention of chronic
complications (e.g., by the adoption of an healthy lifestyle, body
weight control, or moderate physical exercise) may be crucial
to successfully fight against these epidemics. However, as disease
progresses, some pharmacological approach (including combined
therapy) may be required to successfully deal with T2D and its
complications. Therefore, besides more and more efficient (and
with less secondary effects) anti-T2D drugs, it is of the outmost
importance to develop efficient therapies that also minimize any
further damage to the already injured organs, ultimately delaying
or avoiding the development of long-term complications (as AD).
Herewith, we will focus primarily on the impact of T2D
in CNS, particularly in the most common form of dementia,
AD, as well as on some of the currently used anti-T2D drugs.
More specifically, we will briefly overview the pros and cons of
the promising therapeutic potential of a new class of anti-T2D
drugs – the incretin/glucagon-like peptide-1 (GLP-1) mimetics –
with a particular relevance to the role of exendin-4 (Exe-4) on
T2D-associated neurodegeneration.
T2D AND AD: MORE THAN UNRELATED PATHOLOGIES
As previously mentioned, impaired insulin signaling has been crit-
ically involved in the development and progression of both T2D
and AD. However, other abnormalities common to both patholo-
gies include glucose dysmetabolism, mitochondrial dysfunction,
oxidative stress, or deposition of amyloidogenic proteins (2).
Under physiological conditions, glucose metabolism is critical
for proper brain function (and its neuronal connections). As neu-
rons are unable to store and synthesize glucose, this is transported
across the blood–brain barrier (BBB) via glucose transporters
(GLUTs), with GLUT-1, GLUT-3, and GLUT-4 constituting the
most abundant isoforms (16). However, under chronic glucose
dysmetabolism (as in T2D), brain damaging effects may arise, with
the formation and accumulation of advanced glycation endprod-
ucts (AGEs) constituting one of the most deleterious ones (17).
AGEs are formed by a sequence of events originally identified as
the end products of the Maillard reaction, during which reduc-
ing sugars (e.g., glucose and fructose) react with amino groups
from proteins that become auto-oxidized and form cross-linked
complexes and unstable compounds (13). Besides their massive
formation in diabetic patients, AGEs were also found in retinal
vessels, peripheral nerves, kidneys, and CNS of aged patients (18).
Moreover, the extent of amyloid-β peptide (Aβ) glycation by AGEs
has been correlated with its aggregation into senile plaques, as
well as with tau protein hyperphosphorylation and the subse-
quent formation of neurofibrillary tangles (NFTs) (2), ultimately
leading to the abnormal accumulation of both AD neuropatho-
logical hallmarks (13). Strikingly, AGEs may also react with free
radicals, promoting oxidative damage and further exacerbating
cellular injury (11). Therefore, as T2D exacerbates the production
of such deleterious molecules, it is not surprising that AGEs pro-
duction (and eventually the vicious cycle of oxidative stress) may
constitute another putative biochemical link between T2D and
increased risk of AD.
Regarding oxidative stress, mitochondria constitute one of the
major sources and targets of reactive oxygen species (ROS), and
have been increasingly demonstrated to have a pivotal role in AD
and diabetes pathogenesis (19). These organelles are primarily
responsible for several crucial cellular processes, being also the
main coordinators of energy metabolism (by generating over 90%
of cellular ATP) (2). Conversely, given the mitochondria’s high
susceptibility to oxidative stress-mediated injury together with the
neurons’ extreme sensitivity to alterations in their mitochondrial
pool, it is acceptable that the organelles’ functional impairment can
be strictly correlated with AD and diabetes (5). Recently, our group
demonstrated that brain mitochondria from both the 3xTgAD
and chronically sucrose-treated mouse (models for AD and T2D,
respectively) had similarly impaired respiratory chain and phos-
phorylative system that, along with an oxidative dysfunction,
might account for their similar behavioral and cognitive anom-
alies (e.g., augmented fear and anxiety and decreased learning and
memory) (20). Together with the increased brain cortical and hip-
pocampal Aβ levels observed in sucrose-treated mice, these reports
suggested that metabolic alterations usually associated with T2D
could contribute for the development of AD features (20, 21), in
agreement with the previously reported profound mitochondrial
anomalies and increased Aβ and phosphorylated tau protein lev-
els in brain cortex and hippocampus upon CNS-induced insulin
resistance (22), as well as with the higher predisposition of T2D
patients for cognitive decline and eventually AD (23).
INSULIN/INSULIN RECEPTOR SIGNALING: THE MISSING LINK
BETWEEN T2D AND AD?
Insulin was traditionally recognized for the regulation of periph-
eral glucose metabolism (such as in adipose, liver, or muscle
tissues); however, its high levels in brain were also correlated
with a crucial role in CNS (24), particularly in cognition, mem-
ory, learning, and synaptic plasticity, most probably involving the
complex insulin/insulin receptor (IR) signaling pathways (25). The
majority of insulin in brain derives from pancreatic β-cells, being
transported mostly across the BBB (26). However, some periph-
erally produced insulin may also directly diffuse into the CNS
through the area postrema, a circumventricular region with a
“leaky” BBB (27), and even more strikingly, other CNS insulin
molecules may be locally synthesized and exocytotically released
by pyramidal neurons (e.g., from hippocampus, prefrontal cortex,
and olfactory bulb, but not glial cells) (14). Brain insulin binds
rapidly to the highly abundant and ubiquitously distributed IR in
the CNS (26, 28).
Downregulation of insulin uptake in T2D brain may deprive
this organ from the hormone’s beneficial effects (24). Indeed, an
acute increase in peripheral insulin levels may increase insulin
in cerebrospinal fluid, whereas chronic peripheral hyperinsuline-
mia (as in insulin resistance or T2D) may downregulate IRs at
BBB, impair brain insulin uptake (26), and culminate in learn-
ing, memory, and cognition deficits (28–30). These evidences
further support the idea that impaired insulin function and sig-
naling may constitute another common mechanistic link between
diabetes (particularly T2D) and AD (31). This hypothesis was
further reinforced by the role of insulin in the regulation of
the AD neuropathological hallmarks, Aβ and tau. In this regard,
insulin/IR dysfunction has been related with neuronal tau pro-
tein hyperphosphorylation and inhibition of Aβ precursor protein
(AβPP) processing, thereby detaining Aβ accumulation (26). This,
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together with the impairment in the extracellular release of Aβ
for further clearance (as in normal conditions) may further exac-
erbate the deleterious intraneuronal accumulation of Aβ (26).
On the other hand, under an excessive amount of insulin (as in
hyperinsulinemia), the hormone competes with Aβ for insulin-
degrading enzyme (IDE, a metalloprotease that degrades both
insulin and Aβ), allowing for the peptide accumulation and for-
mation of senile plaques (32). However, Ho et al. reported that
both diet-induced insulin resistance and a hyperinsulinemic state
in an AD-like model was associated with lower IDE levels and Aβ
accumulation (33), whereas Pedersen et al. showed that rosigli-
tazone administration (an insulin sensitizer) improved learning
and memory and simultaneously reduced Aβ1–42 levels (the main
pathological form of Aβ in brain tissues) (34). These results sug-
gested that rosiglitazone-mediated stimulation of insulin signaling
could lead to a decrease of the hormone available to compete
with IDE, therefore promoting Aβ degradation (34). Further evi-
dences on an insulin-mediated neuroprotection were previously
shown by our group, with insulin decreasing both apoptotic and
necrotic neuronal death upon oxidative stress, via the activation of
IR/IGF-1 receptor (IGF-1R) and subsequent inhibition of glyco-
gen synthase kinase-3β (GSK-3β) (35). This was accompanied by
a protection against neuronal lipid and protein oxidation, particu-
larly the increase in the formation of 4-hydroxynonenal (4-HNE,
a byproduct of oxidation) adducts on neuronal GLUT-3 trans-
porters upon oxidative stress (35). As a result, insulin was able
to stimulate neuronal glucose uptake and its metabolization into
pyruvate (in a PI3K- and ERK1/2-mediated signaling), restoring
intraneuronal energy levels (36). Accordingly, we also described an
insulin-related modulation of the transport of the amino acid neu-
rotransmitters GABA and glutamate, both in T2D and/or oxidative
stress (37, 38).
Insulin-like growth factors-1 (IGF-1) and -2 (IGF-2) and
relaxin were shown to share structural similarities with insulin,
all belonging to the same protein family (39). Similar to insulin,
IGF-1 crosses the BBB, being ubiquitously distributed in rodent
and human brains, and widely affecting CNS (9, 40). Hence,
insulin/IR- and IGF-1/IGF-1R-mediated signaling seem to play
a key role in the regulation of brain glucose metabolism, neu-
ronal growth and differentiation, neuromodulation, synaptic
transmission, memory/learning, and neuroprotection (14). For
instance, in vivo T2D-associated impaired insulin and IGF-1 sig-
naling was accompanied by neuronal loss, neurite degeneration,
AβPP dysmetabolism and tau protein hyperphosphorylation (41,
42). Moreover, insulin may protect against neuronal apopto-
sis via activation of mitogen-activated protein kinase (MAPK)
signaling (namely p38 MAPK) and suppression of caspase-3
activity, a pathway that may also play a role in memory and
learning (25).
CAN ANTI-T2D THERAPIES BE POTENTIAL ANTI-AD THERAPIES?
It seems unquestionable that T2D and AD are two intrinsically
related pathologies sharing several common mechanisms. There-
fore, it has been hypothesized that a treatment directed against
T2D may be beneficial in AD. Several groups worldwide have been
analyzing anti-T2D drugs (either in clinical use or under clinical
trials) in the context of AD. This might be facilitated by the wide
range of anti-T2D compounds established, accepted, and being
used worldwide; however, there are probably many more under
development or awaiting approval [we must remind that T2D is a
highly concerning, modern epidemic (43)].
“Modern” anti-T2D treatment: reaching euglycemia is essential, but
not sufficient
The maintenance of glycemic control within the normal range
constitutes an efficient first approach to reduce the risk of T2D-
associated long-term vascular and cardiovascular complications.
But, as disease progresses, its successful management may also
include the control of blood pressure and lipid levels (44). There-
fore, although the achievement of an optimal glycemic control
remains the main goal of diabetes therapeutic management, lately
this may not be enough to reduce cardiovascular risk (45).
Some of the currently used anti-diabetics include oral [e.g.,
biguanides, sulfonylureas (SUs), thiazolidinediones (TZDs), and
dipeptidyl peptidase-IV (DPP-IV) inhibitors] (46) and injectable
agents (e.g., insulin and GLP-1 analogs) (44). Other recent
therapies (either under development or awaiting validation)
include glucokinase activators, amylin analogs, D2-dopamine ago-
nists, bile acid chelators, and sodium/glucose-linked transporter-2
(SGLT-2) inhibitors (47).
Based on the outcomes of several trials, e.g., Action in Dia-
betes and Vascular disease: preterAx and diamicroNmr Controlled
Evaluation (ADVANCE), action to control cardiovascular risk in
diabetes (ACCORD), and veterans affairs diabetes trial (VADT),
recent guidelines establish that therapeutic achievement of eug-
lycemia should imply a patient-adjusted prescription that consid-
ers specific patient/disease factors (47). Among the several risk
factors for T2D, obesity has been one of the closest related with
the disease progression and development of late complications. As
such, patients’ elevated body weight should be considered when
prescribing an anti-T2D treatment (48). This is even more relevant
as body weight gain is a frequent secondary effect of some anti-
T2D therapies (48). As such, the development of several recent
drugs had into account their effects on adipogenesis and fat mass
regulation (49).
Despite the controversy on the ideal levels of glycated hemoglo-
bin A1C (HbA1C), it is more or less consensual that T2D treatment
should aim at lowering its levels (50). HbA1C is a form of glycated
hemoglobin that indirectly estimates the average plasma glucose
levels in the last 2–3 months, giving an idea on the “long-term”
(rather than “acute”) control of blood glucose levels (51). Accord-
ing to the United Kingdom Prospective Diabetes Study (UKPDS)
and diabetes control and complications trial (DCCT), lowering
HbA1C levels by 1.0% reduces microvascular complications by
~30%, and the risk for myocardial infarction and death after
10 years of intensive glucose control in patients with newly diag-
nosed T2D (52). Therefore, the starting HbA1C value is important
when choosing a treatment for each T2D patient, given that most
oral anti-hyperglycemic agents can reduce its values by 1.5–2.0%
from baseline levels of 8.5–9.5% (53). Thus, a patient with a base-
line HbA1C level higher than 9.0% will probably not achieve the
therapeutic goal of <7.0%, suggesting that these patients may
require a combination therapy in a near future (45). Another
important therapeutic target in T2D patients should be a reduction
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in insulin resistance (e.g., with diet, exercise, and/or drug therapy)
and/or a stimulation in insulin secretion (54). However, in the later
stages of disease, when its control remains inefficient, injections of
exogenous insulin may be also needed (3), with the inconvenience
of, e.g., repeated insulin-induced hypoglycemic episodes. In this
regard, several novel agents are being developed to better address
T2D pathogenesis with a minimum risk for hypoglycemia and/or
other associated risk factors (as obesity).
Anti-T2D drugs with a potential against AD
Biguanides. Metformin, derived from extracts of the French Lilac
(55), is the best known biguanide and remains the anti-T2D drug
of choice to initiate the pharmacological approach. It is highly
efficient in improving glycemic control, is not expensive (45) and
has a low risk for hypoglycemia (56). Being an insulin sensitizer,
metformin does not stimulate insulin secretion directly; instead,
it reduces insulin-mediated hepatic glucose production (57) and
increases peripheral glucose disposal, most likely as an indirect
consequence of reduced glucotoxicity (47,58). Regarding its effects
on body weight, some controversy exists, with some authors
describing that metformin did not affect body weight (56),whereas
others reported a metformin-induced weight loss (49). This drug
can be used at all stages of T2D progression, either as monotherapy
or in combination with SUs and other secretagogues (e.g., megli-
tinides), TZDs, and insulin (47, 58). Metformin’s adverse effects
include gastrointestinal distress (e.g., abdominal pain, nausea, and
diarrhea in up to 50% of patients), hepatic dysfunction, congestive
heart failure, dehydration, and alcoholism (58) and, thus, must be
avoided by patients with increased risk for lactic acidosis (such as
those with renal dysfunction) and in elderly ones (45).
Intracellularly, metformin has been shown to inhibit the mito-
chondrial respiratory chain complex I, thus rising AMP/ATP ratio,
with the subsequent AMP binding to (and activation of) the ser-
ine/threonine kinase AMP-activated protein kinase (AMPK), an
important fuel sensor and regulator (49, 59). Dimethylbiguanide
inhibits cell respiration via an indirect effect targeted on the
respiratory chain complex I (60–62). This is of the outmost
importance, as AMPK is able to sense inappropriate AMP/ATP
ratio (insufficient energetic reserves), being turned on after an
increased ATP demand or in response to metabolic stresses (e.g.,
ischemia, hypoxia, hypoglycemia, or increased intracellular cal-
cium levels). This kinase is also modulated by hormones and
cytokines in order to restore cellular energy homeostasis (63).
Importantly, such AMPK activation requires the phosphoryla-
tion of threonine-172 by the LKB1/STRAD/MO25 complex and
the calmodulin-dependent protein kinase kinase-β (CAMKKβ)
(63). And when this occurs, catabolic pathways (as fatty acid
oxidation or glucose transport) that generate ATP are induced,
whereas ATP-consuming, anabolic processes (namely fatty acid
and protein synthesis) are switched off (49). Additionally, AMPK
activation has been suggested to indirectly improve hepatic insulin
sensitivity (47, 49), to promote GLUT-4 protein expression and
glucose uptake in human adipocytes (64) and to regulate adi-
pogenic differentiation via inhibition of peroxisome proliferator-
activated receptor gamma (PPAR-γ) (49). In parallel, metformin
was also described to inhibit adenylate cyclase (AC) via accu-
mulation of AMP and related nucleotides, thus reducing cyclic
FIGURE 1 | Effects of some anti-T2D therapies – crosstalk between
peripheral system and CNS. Some of the treatments directed against T2D
include biguanides, sulfonylureas (SUs), thiazolidinediones (TZDs), and the
more recent incretin-based therapies, dipeptidyl peptidase-IV (DPP-IV)
inhibitors and glucagon-like peptide-1 receptor (GLP-1R) agonists. In T2D
patients, a few treatment goals include decrease of hyperglycemia (a
typical feature of T2D), glycated hemoglobin (HbA1C), and total cholesterol
levels. Another objective is the decrement in insulin resistance and
increased endogenous insulin secretion, as in both T2D and AD insulin
signaling pathways may be impaired. Some anti-T2D therapies may also
positively affect CNS, namely via counteracting oxidative stress,
mitochondria dysfunction, and neuronal death, together with the
stimulation of neurogenesis and synaptic function. These therapies also
decreased amyloid β (Aβ) accumulation and hyperphosphorylated tau
protein, suggesting that they may be beneficial against AD.
adenosine monophosphate (cAMP) levels and protein kinase A
(PKA) activity in mouse hepatocytes, culminating in ablation of
glucagon-dependent glucose production and output (49).
Regarding the role(s) of metformin in CNS, our group showed
that metformin protects T2D rat brain against oxidative stress [e.g.,
thiobarbituric acid reactive substances (Figure 1) and malondi-
aldehyde levels], probably by inhibiting the antioxidant enzymes
glutathione peroxidase (GPx) and glutathione reductase (GRed),
by improving the levels of the non-enzymatic antioxidant glu-
tathione (GSH) and by stimulating manganese superoxide dis-
mutase (MnSOD) activity (65). Additionally, Guigas et al. (66)
observed that metformin protected primary cortical neurons
against apoptotic death. These observations, together with: (1)
the inhibition of AMPK upon insulin resistance and the subse-
quent deterioration of energy supply, development of neuroin-
flammatory processes, and AD-related neurodegeneration; (2) the
lower AMPK activity upon aging that may also contribute for the
lower mitochondrial biogenesis and function reported in AD; (3)
the protection against oxidative stress, impaired glucose trans-
port and mitochondrial function, as well as Aβ accumulation in
AD; and (4) the widely described involvement of dysfunctional
brain energy metabolism (e.g., insulin resistance, impaired glucose
uptake, mitochondrial and cholesterol metabolism dysfunctions,
disturbed calcium homeostasis, and oxidative stress) in cognitive
dysfunction and AD, led to the recent hypothesis that AMPK
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activation could represent a novel potential target for the treat-
ment of neurodegenerative diseases, including AD (26, 63, 67).
In line with this, the roles of metformin on the reduction of
insulin resistance (Figure 1), plasma fasting insulin levels, glu-
cose, lipid and protein synthesis, and cell growth, also stimulating
fatty acid oxidation (68–70), (most of them common features to
T2D and AD and involving LKB1-induced AMPK activation) ren-
dered this drug a promising therapeutic approach also against AD
(Figure 1) (62, 63). This hypothesis is further supported by the
recent observations that metformin prevented the accumulation
of AD-like molecular and pathological features in a differentiated
neuronal cell line submitted to chronic hyperinsulinemia, includ-
ing Aβ generation and tau protein hyperphosphorylation (71, 72).
Although the precise underlying mechanisms are still under inves-
tigation, it is possible that such protection may occur via the
activated AMPK-associated regulation of amyloid precursor pro-
tein (APP) processing and tau protein phosphorylation (AMPK is
a physiological tau protein kinase) (63). Alternatively, metformin-
induced AMPK activation may further inhibit the downstream
mTOR signaling, thus promoting autophagy and lysosomal degra-
dation of Aβ (63). Moreover, Kickstein et al. (62) proposed that
by increasing the phosphorylation of mTOR and its downstream
targets p70S6 kinase, S6, and tau proteins in primary cultured
neurons, metformin and its derivative phenformin could then
activate PP2A, thereby efficiently dephosphorylating tau protein.
Interestingly, such effect of metformin on PP2A activity could
also overcome a reduction in GSK-3β phosphorylation at serine 9
(and its subsequent activation), thus helping in the attenuation of
neuronal tau protein phosphorylation, via an AMPK-independent
pathway (62).
However, such promising anti-AD potential afforded by met-
formin, must be faced with caution, as more research is needed to
clarify some of the controversial observations reported, as well
as the underlying molecular mechanisms. Indeed, Chen et al.
suggested that metformin could exacerbate AD pathology, as it
promoted both intra and extracellular production of Aβ, probably
via the AMPK-dependent transcriptional upregulation of BACE1
(73). Moreover, Li et al. (71) reported recently that, despite the
amelioration in c-Jun-N-terminal kinase activity (JNK, a kinase
known to increase tau protein phosphorylation) and in hip-
pocampal expression of the synaptic protein synaptophysin in
the metformin-treated db/db mouse model of T2D, this was not
accompanied by an amelioration of spatial learning and memory
impairments. Even other authors reported that AMPK activation
could be detrimental, e.g., in stroke and Huntington disease (74–
77). Our group also reported that metformin could exacerbate
rat liver cell death via induction of hepatic mitochondrial dys-
function (78), in accordance with the widely described hepatic
dysfunction associated with metformin (79). Therefore, it seems
that depending on the conditions and biochemical settings,AMPK
(and ultimately metformin) might be a two-edged sword regarding
Aβ production and tau protein phosphorylation, and ultimately
AD pathology (63). In this perspective, we believe that it will
be of outmost importance to unravel if AMPK activation plays
a causative or a protective role, if this is a consequence of AD
and if this is clinically beneficial in humans (63), e.g., concerning
metformin or other AMPK-stimulating compounds.
Sulfonylureas. As previously referred, SUs are used as monother-
apy or combined with other oral agent classes and insulin (46).
Second-generation SUs (glyburide, glipizide, and glimepiride) are
more potent and probably safer than the first-generation ones
(chlorpropamide, tolbutamide, acetohexamide, and tolazamide),
but have a similar efficacy (46). These drugs are the second lead-
ing choice (after the biguanide metformin) in anti-hyperglycemic
agents worldwide, most likely because they are rather inexpensive
and quite efficient (47). Although SUs treatment aims essentially
at lowering blood glucose and to allow for insulin release at a lower
glucose threshold than normal, we must bear in mind that these
drugs also appear to increase the risk of hypoglycemia (particularly
in elderly patients with renal dysfunction, and/or with irregular
meal schedules) (46, 47). Moreover, a clinical trial showed that SUs
were able to decrease HbA1C up to 7.4% (80), but it has been more
commonly reported only a modest 1–2% lowering (81). Others
described that SUs reduced hypercoagulation and cardiovascular
damage, and modestly protected pancreatic islet cells against the
progressive cellular deterioration upon T2D (45). However, in an
early clinical trial, Kilo et al. (82) observed that although SUs-
treated patients had an increased cardiovascular mortality, overall
there were no significant differences between SU-treated subjects
and those treated with insulin. Importantly, another highly rele-
vant issue in SUs therapy is weight gain (typically from 2 to 5 kg),
which might be of the outmost importance in the context of the
above-mentioned close relation between diabetes and obesity (58).
Finally, as most of these drugs are metabolized in liver and cleared
by the kidney, some cautious is needed regarding patients with
advanced forms of either hepatic or renal disability (46).
Despite the limited knowledge on the precise molecular mech-
anisms involved in SUs-induced insulin secretion, it has been
suggested that, after their binding to the SU receptors at the sur-
face of pancreatic β-cells, ATP-sensitive potassium (KATP) chan-
nels are closed, cell membrane depolarization and calcium influx
occur, ultimately leading to the glucose-independent insulin secre-
tion (46, 47) (Figure 1). Alternatively, others suggested that SUs
may have PPAR-γ agonist activity (49). Also, unclear is the SUs-
induced stimulation of insulin action in adipocytes, with some
data pointing toward an SU receptor-independent mechanism, as
the receptors are not expressed in adipose tissues (83). Regarding
the eventual SUs’s potential therapeutic action against dementia
and AD, evidences from literature are scarce. In a recent study,
Exalto et al. (84) reported that the occurrence of dementia in
SUs-treated T2D patients was decreased and, although a correla-
tion between the specific actions of the drug per se and improved
glycemic control could be involved herein (85) (Figure 1), the pre-
cise mechanisms remain unknown. Thus, further investigation to
clarify the molecular mechanisms of action of SUs (particularly in
CNS and in AD-dementia type) is needed before assuming their
anti-AD potentialities.
Thiazolidinediones. The members of this class of drugs (also
named glitazones and currently represented by rosiglitazone and
pioglitazone) act as agonists of PPAR-γ, a nuclear receptor highly
expressed in insulin-sensitive tissues (e.g., adipocytes, liver, and
pancreas) that regulates the transcription of genes involved in
lipid and glucose metabolism (45, 49). Once activated, PPAR-γ
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stimulates adipocyte differentiation (86) and decreases hepatic
glucose production (87). Additionally, in placebo-controlled tri-
als, TZDs were as efficient as SUs and metformin in decreasing
HbA1C levels, but more efficient than α-glucosidase inhibitors
(46). Moreover, TZDs were more efficient in maintaining long-
term cell function and glycemic control than metformin (45), and
to decrease insulin resistance in peripheral tissues (88) (Figure 1),
with data suggesting that TZDs may actually prolong β-cell sur-
vival (89). However, TZDs have been increasingly associated with
a few problematic side effects: (1) relatively expensive, (2) weight
gain, (3) fluid retention, and (4) increased myocardial infarc-
tion risk, particularly by the use of rosiglitazone (which has been
restricted in the United States and even suspended in the Euro-
pean Union). On the other hand, although pioglitazone appeared
to reduce major cardiovascular events and death (90), its use has
been also linked with an increased risk to fractures and bladder
cancer (47).
Regarding the intracellular effects of TZDs, it is known that
their action is not to stimulate insulin secretion by pancreatic
β-cells directly (in fact, its local concentrations usually remain
low); rather, TZDs aim at enhancing β-cells’ sensitivity and effi-
ciency (91), most likely by decreasing circulating glucose and free
fatty acid levels (both having deleterious effects on insulin secre-
tion), through their collection in adipose tissue (92). Although the
molecular mechanisms underlying the insulin-stimulated glucose
uptake (e.g., by skeletal muscle cells) upon TZDs treatment (one
of their most prominent effect) remain mostly unclear, it has been
proposed that this might largely occur indirectly via the interaction
between TZDs and adipocytes (49). The resulting upregulation of
GLUT-1 and GLUT-4 would then improve glucose disposal and
consequently reduce its toxicity (49). Despite the lack of knowledge
on the intermediary signal(s) between fat and muscle, it is possi-
ble that leptin, free fatty acids, tumor necrosis factor α (TNFα),
adiponectin, and the more recently isolated resistin could play a
role (46).
Similarly to SUs, evidence on the anti-AD potential of TZDs is
scarce and, in our perspective, this might be due to not only the
lack of information on the precise molecular mechanisms under-
lying their effect(s) (particularly in brain) but also the limitations
currently posed to their therapeutic use in T2D patients world-
wide due to their potentially serious side effects. Nevertheless, in
2005, Dormandy et al. reported that TZDs downregulated in vitro
Aβ deposition, whereas Neumann et al. (93) observed that trogli-
tazone reduces tau protein phosphorylation at serines 202 and
396/404 (known to be phosphorylated in early and later stages in
AD, respectively, as well as in other neurodegenerative patholo-
gies) (Figure 1). This, together with the rosiglitazone-induced
preservation of memory function and selective attention and the
decrement in plasma levels of Aβ1–40 and Aβ1–42 in AD patients
AD (94, 95). However, this hypothesis deserves further investiga-
tion and should be faced carefully given the adverse side effects
of TZDs.
Insulin. Insulin is the best known anti-type 1 diabetic drug, being
a life-saving treatment in these patients. Regarding T2D indi-
viduals, although insulin has been increasingly used to control
their blood glucose levels and prevent chronic complications, its
efficiency still remains controversial (47, 96). Currently, several dif-
ferent human insulin formulations and insulin analogs are avail-
able commercially, aiming at “personalizing,” as closely as possible,
the normal insulin physiology (47) and thereby minimizing its
high risk for hypoglycemia (45).
Besides the above-mentioned relevance of insulin in both T2D
and AD brains (particularly endogenous insulin and/or its down-
stream signaling cascades), in terms of exogenously administered
hormone, it is of the outmost importance to refer that insulin-
induced hypoglycemia has been long associated with neurological
and cognitive deficits, seizures, coma, and neuronal death (97),
particularly in hippocampus, external cortical layers and striatum
(98). Although the mechanisms involved herein remain poorly
understood, our group has recently demonstrated that insulin-
induced hypoglycemia impairs brain mitochondria function and
increases oxidative stress (99, 100), leading to a parallel increase
in plasma and/or brain cortical aspartate, glutamate, glutamine,
and taurine, and a lowering in GABA levels in rats submitted
to an acute episode of insulin-induced hypoglycemia (96). This
was accompanied by a further release of aspartate, glutamate, and
taurine from depolarized hypoglycemic synaptosomes, suggesting
that an additional metabolic insult may be sufficient to exacerbate
the release of excitatory aminoacids. Therefore, this may constitute
an additional mechanism underlying diabetes (and, more partic-
ularly, insulin-induced hypoglycemia)-associated neuronal injury,
degeneration, and cognitive impairment (96). In this perspective,
besides these adverse effects, we must be aware that exogenously
added insulin has been demonstrated to play several beneficial
roles in CNS, with the ubiquitous localization of IRs in hippocam-
pus, entorhinal, and frontal cortices further pointing toward the
hormone’s benefits in brain. Moreover, the primary location of IRs
at the synapses, where their signaling may contribute to synaptic
remodeling (together with a role on memory formation under nor-
mal metabolic conditions) (101), and the long known modulatory
role for insulin against deleterious Aβ synaptic accumulation and
effects (42), further suggest that insulin administration (without
hypoglycemic episodes) or, even better, the pharmacologic restora-
tion of brain insulin sensitivity and action could be one of the best
promising therapeutic approaches against AD.
Incretins/GLP-1 receptor agonists and DPP-IV inhibitors: the
“dream team”? From the above, one of the most efficient ther-
apeutic approaches to T2D (and apparently also against neu-
rodegeneration and AD) are the novel classes of GLP-1 analogs
and DPP-IV inhibitors. Incretins are gastrointestinal hormones,
first identified in the 1960s, when a glucose load was observed
to increase insulin secretion (102). This was due to the secre-
tion of both GLP-1 (an incretin of 30 amino acid length) and
glucose-dependent insulinotropic polypeptide [also called gas-
tric inhibitory polypeptide (GIP)], by enteroendocrine K and
L cells, respectively (44, 103). Recently, it was described that,
together, both hormones account for the majority of glucose-
dependent insulin production, secretion, and response (1, 103).
Indeed, the earliest endocrine metabolism activated after a meal is
the insulinotropic incretin effect that consists on the activation of
the potent insulinotropic GLP-1 immediately after GIP secretion
(104). Although the precise mechanisms involved herein remain
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somehow controversial, it is plausible that they may involve both
central and peripheral effects of GLP-1 to promote insulin and
inhibit glucagon secretion (thus dealing with the post-prandial
rise in glycemia and the maintenance of blood glucose homeosta-
sis) (1, 103, 104), reduce gastric emptying, appetite, food intake,
and body weight (47, 103, 105–107).
Molecularly, GIP and GLP-1 bind and activate structurally dis-
tinct G-protein-coupled receptors (GPCRs) (27), with GIP recep-
tor being predominantly expressed on islet β-cells and (to a lesser
extent) in adipose tissue and in CNS, whereas GLP-1 receptor
(GLP-1R) occurs in islet α and β cells, as well as in central and
peripheral nervous systems, heart, kidney, lung, and gastrointesti-
nal tract (27). Under physiological conditions, insulin secretion
may depend on the GLP-1 receptor (GLP-1R)-mediated aerobic
metabolization of glucose through glycolysis and the subsequent
raising in cytosolic ATP levels (108). As a consequence, the hyper-
polarizing KATP channels close, β-cell membrane depolarization
occurs, allowing calcium influx through voltage-dependent cal-
cium channels (VDCC) occurs and calcium-dependent insulin
exocytosis is potentiated (105, 106, 108) (Figure 2). Alterna-
tively, insulin secretion may be stimulated by intracellular sig-
naling cascades involving, e.g., cAMP or its downstream tar-
get Epac (exchange protein activated by cAMP), PKA, AMPK,
protein kinase C (PKC), and MAPK, as it has been described for
GLP-1-mediated stimulation of glucose-dependent insulin release
(108). As blood glucose levels return to normal, GLP-1-induced
insulin exocytosis is decreased (45, 103). Despite all this, the
effects of incretins on pancreatic β-cell intermediary metabolism
to promote insulin secretion still remain controversial. Tsuboi
et al. reported that GLP-1 is able to modulate β-cell interme-
diary metabolism (and function) at both low and high glucose
levels, probably by changing cytosolic ATP content in a GLP-1R-
dependent manner (109). Conversely, others failed to observe any
effect of exendin-4 (a GLP-1R agonist) on mitochondrial ATP lev-
els in primary rodent islets (110), despite the large oscillations
in intracellular calcium, and the subsequent activation of ATP-
consuming and – production processes (and, thereby, of cellular
metabolism) to maintain intracellular calcium homeostasis (108).
Alternatively, Burmeister et al. (106) proposed recently that GLP-
1R-associated increase in glucose metabolism after a meal could
initiate a feedback inhibition of food intake, mediated by a decre-
ment in AMPK activity. As such, glucose could be considered as
both a stimulus and a mechanistic component of GLP-1-mediated
suppression of food intake (106).
Circulating human GLP-1 has a short half-life (1–2 min),
being almost completely degraded by DPP-IV (111), an ubiqui-
tously expressed aminopeptidase that occurs, e.g., in liver, lung,
kidney, endothelium, and lymphocytes, and is essential for incretin
FIGURE 2 | Mechanisms of first phase of insulin secretion by GLP-1
mimetics. GLP-1 and GLP-1R agonists exert their actions by binding to
GLP-1R, a G-protein-coupled receptor (GPCR). GLP-1R is ubiquitously
expressed throughout the whole body, including peripheral and central
nervous systems. Despite some controversy, it has been hypothesized that
incretin receptor activation in β-cells after a meal leads to glucose
metabolization through glycolysis and the subsequent increase in cytosolic
ATP content. Then, the hyperpolarizing KATP channels close and β-cell
membrane depolarizes, allowing calcium influx to occur via the
voltage-dependent calcium channels (VDCC) and culminating in
calcium-dependent insulin exocytosis. Alternatively, insulin secretion may be
also stimulated by intracellular signaling cascades involving, e.g., cyclic AMP
(cAMP) or its downstream targets Epac (exchange protein activated by
cAMP), protein kinase A (PKA), AMP kinase (AMPK), protein kinase C (PKC),
or MAPK. As blood glucose levels return to normal, GLP-1-induced insulin
exocytosis is decreased.
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inactivation (112). This renders the therapeutic use of the nat-
urally occurring human GLP-1 highly unfeasible; thus, several
long-acting GLP-1R agonists that mimic the effects of endogenous
GLP-1 and more resistant to DPP-IV-mediated degradation have
been developed as anti-T2D therapies (113). In line with this, mice
with targeted downregulation of DPP-IV showed higher plasma
levels of GIP and GLP-1, increased insulin secretion, and reduced
glucose release (114), whereas DPP-IV inhibitors were reported to
reduce HbA1C levels by 0.7% in T2D patients undergoing met-
formin therapy (115) (Figure 1). Besides incretins, other DPP-IV
substrates include other gastrointestinal hormones, neuropep-
tides [e.g., neuropeptide Y (NPY)], cytokines, and chemokines
(103) that may also affect lipid metabolism and adipogenesis (49).
Indeed, blockade of the NPY receptor was reported to inhibit the
DPP-IV-mediated stimulation of lipid accumulation (49). Similar
to GLP-1 analogs, DPP-IV inhibitors often become less effective
as insulin resistance progresses and pancreatic β-cells function
deteriorates (113). In general, DPP-IV inhibitors are well tol-
erated, can be given orally to lower fasting and post-prandial
glucose, apparently without affecting gastric emptying or body
weight (45, 49). These drugs can be used either as monotherapy
or together with other oral agents or insulin. Amongst DPP-
IV inhibitors, sitagliptin, saxagliptin, and linagliptin have been
approved by the FDA, whereas vildagliptin is available in the
European Union and alogliptin in Japan (47). At their recom-
mended doses, a daily administration of these DPP-IV inhibitors
prevented DPP-IV activity for at least 24 h, with the exception
of vildagliptin that required a twice daily administration (116).
Importantly, as ~80% of non-metabolized sitagliptin, alogliptin,
and saxagliptin were detected in urine (renal excretion is their
main excretory pathway), DPP-IV inhibitors may require an addi-
tional dose adjustment in patients with impaired renal function
(116). Regarding vildagliptin, it is metabolized mostly by the liver,
not being recommended to patients with hepatic insufficiency
(47), whereas linagliptin is only minimally metabolized and, thus,
78% of the administered dose is excreted unchanged by the hepa-
tobiliary route via the feces, being other 5% excreted through the
kidney (116). In this perspective, linagliptine could be an attractive
therapeutic option for T2D patients with moderate, severe, or end
stage renal disease; nevertheless, it should be prescribed cautiously
to patients with hepatic insufficiency (47).
Importantly herein, recent studies showed that sitagliptin
delayed the development of AD neuropathological hallmarks
in an adult, double transgenic mouse model of AD (117), or
even improved learning behavior in adult, insulin-resistant rats
(117, 118). More specifically, chronic administration of sitagliptin
reduced both hippocampal APP and Aβ deposition in the trans-
genic AD mice (117) (Figure 1), whereas in the insulin-resistant
rats, it promoted a decrease in plasma insulin, cholesterol, and
HDL levels, and ameliorated the HOMA values (an index of insulin
resistance) (118). Additionally, both vildagliptin and sitagliptin
were able to protect against oxidative stress in insulin resistance
rats (118) (Figure 1). Despite these promising results of DPP-
IV inhibitors’ administration against such deleterious conditions
for the rodent brains, the knowledge on the precise underlying
mechanisms remains scarce and will be of the outmost relevance
in the context of the DPP-IV inhibitors’potential as anti-AD drugs.
Clinical studies comparing GLP-1R agonists vs. DPP-IV
inhibitors revealed that exenatide or liraglutide (GLP-1R agonists
currently used in T2D treatment) were more efficient than
sitagliptin (a DPP-IV inhibitor) in lowering blood glucose levels,
upon hyperglycemia (Figure 1), and body weight in T2D patients
(1, 119). Conversely to insulin and other oral anti-T2D, the risk
of hypoglycemia was also low and comparable between GLP-1R
agonists and DPP-IV inhibitors (47), thereby constituting an addi-
tional advantage for their possible application in AD treatment, as
further discussed in the next section.
GLP-1 analogs and GLP-1R agonists: what is effective against
T2D could be also effective against neurodegeneration and AD?
As previously described, a crucial peripheral effect of GLP-1
analogs and GLP-1R agonists is to promote β-cell function, since
β-cell mass and function are often already impaired at the time
of T2D diagnosis (1). Amongst the clinically available long-acting
GLP-1 analogs for the treatment of T2D, liraglutide is the mostly
used one, either as mono- or combined therapy with metformin
or TZDs (47). Liraglutide shares 96% structural resemblance with
human GLP-1 and besides its traditional role in lowering blood
glucose levels toward euglycemia, it has been also shown to reduce
systolic blood pressure, as well as to decrease the risk for hypo-
glycemia when combined with SUs (47). Importantly, given such
interesting features of these incretin hormone’s analogs (with a
special emphasis on their unique feature of promoting glucose-
dependent insulin secretion with only a minimal risk of damage
associated with repeated hypoglycemia episodes), intense research
efforts have been done to clarify their precise molecular mech-
anisms of action and, simultaneously, to develop and test other
similar drugs.
Given that GLP-1 is ubiquitously expressed in CNS, particu-
larly in hypothalamus, cortex, hippocampus, striatum, substantia
nigra, brain stem, and subventricular zone (an area of adult brain
neurogenesis) (113), it is not surprising that not only GLP-1’s
main peripheral roles might be centrally controlled but also that
this incretin and its analogs may play a pivotal role in brain
(Figure 1). In fact, as brain GLP-1 has been increasingly suggested
to be neuroprotective, it is possible that the modulation of its
specific receptor may represent a promising strategy against neu-
rodegeneration/death and memory and cognition impairment,
i.e., it may constitute a putative pharmacological target against
age- and/or T2D-related neurodegenerative diseases, including
AD. In line with this, During et al. observed that knockout mice
for GLP-1R had memory and learning deficits (120). Additionally,
the GLP-1 analog liraglutide was shown to prevent hippocampal
synaptic loss and plasticity (Figure 1), and memory impairment
in the APP/PS1 mouse model of AD (121). Recently, other authors
reported that liraglutide hampered Aβ plaque formation (122)
(Figure 1), reduced astrocyte- and microglia-mediated inflam-
matory responses (123), and promoted neurogenesis (Figure 1)
and neuronal proliferation in dentate gyrus (124). Although
these results point toward the beneficial use of liraglutide as an
anti-AD pharmacological approach, further clarifying research
is needed, with a particular emphasis on the ongoing clinical
trials (“Identifying potential effects of liraglutide on degenera-
tive changes” – ClinicalTrials.gov Identifier: NCT01469351; and
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“Evaluating liraglutide in Alzheimer’s disease” – ClinicalTrials.gov
Identifier: NCT01843075).
Besides GLP-1 analogs (as liraglutide), the incretin class of anti-
T2D drugs also include the GLP-1R agonists. Amongst them, the
most widely clinically used and best studied is exenatide (exendin-
4, Exe-4), a highly effective molecule against T2D (125). Exenatide
is a synthetic injectable GLP-1R agonist resistant to DPP-IV, being
derived from Exe-4 (a peptide obtained from the saliva of the Gila
monster, Heloderma suspectum) (126). Exe-4 shares a 53% amino
acid sequence identity with human GLP-1, being more effective in
lowering glucose levels than the native hormone (103). Clinically,
Exe-4 constitutes an important complement to diet and exercise
in the improvement of glycemic control in T2D adults (1), either
when used as a monotherapy or in combination with other oral
anti-T2D agents (127). Additionally, Exe-4 decreases food intake
(128) and, together with metformin and/or SUs, lowers HbA1C
levels by 0.8–0.9% (Figure 1) and reduces body weight by 1.6–
2.8 kg (129). Interestingly, exenatide promoted graft survival and
function after islet-cell transplantation in T1D patients (130).
Although the molecular mechanisms involved in the potent
effects of Exe-4 on glucose-dependent insulin secretion (Figure 1)
and insulin gene expression (131) are still under intense research,
it is possible that they may involve drug binding and activa-
tion of GLP-1R in pancreatic β-cells. These receptors belong to
the G-protein-coupled class of receptors, activating adenyl cyclase
and rapidly increasing cAMP levels, thus promoting downstream
intracellular signaling cascades (27) that may culminate in the
modulation of β-cell proliferation and function, as well as in the
inhibition of apoptosis (103, 128). Importantly, some patients
treated with exenatide reported some transient secondary effects,
including nausea, vomiting, and diarrhea (103, 132) and, more
rarely, pancreatitis (133).
Given its stability in blood and high lipophilicity, most of the
peripherally injected Exe-4 crosses the BBB without being trapped
by endothelial cells and rapidly reaches the brain (104). Addi-
tionally, Exe-4 action is insensitive to food deprivation for 24 h
(134). Besides the periphery, GLP-1R is also highly expressed in
CNS (135) and, therefore, it is conceivable that the activation of
downstream GLP-1R-mediated signaling molecules may at least
partially be involved in Exe-4-mediated stimulation of neuroge-
nesis in subventricular zone (136), neurite outgrowth, neuronal
differentiation, rescue of degenerating neuronal cells, and protec-
tion against both in vitro and in vivo excitotoxic damage (137)
(Figure 1). However, the underlying mechanisms remain poorly
understood and deserve further clarification. In clinical studies,
Exe-4 was shown to promote cellular neogenesis, proliferation, and
apoptotic death inhibition (131). In adult rodents, it was shown
to improve hippocampus-associated behavior (138) and to pro-
tect against neuroinflammation (132). Moreover, Exe-4 protected
against Aβ-associated hippocampal neuronal death (Figure 1)
and rescued learning and memory in intracerebroventricularly
injected streptozotocin rats (a model of sporadic AD) (1). Thus,
besides its high relevance and efficacy in the therapeutic man-
agement of T2D, Exe-4 is also faced as a promising drug for the
treatment of dementia and AD. In this regard, we believe that
the results from the ongoing clinical trial “A pilot clinical trial of
exendin-4 in Alzheimer’s disease” – ClinicalTrials.goc Identifier:
NCT01255163, will be of the outmost relevance herein.
Amongst the novel GLP-1R agonists, lixisenatide and albiglu-
tide are currently undergoing phase III clinical trials. Lixisenatide
is based on exendin-4 (1–39) molecule and has a modified C-
terminal with six additional lysine residues that confers a fourfold
higher affinity to the GLP-1R than the human GLP-1, together with
a half-life of about 3 h (139, 140). Similar to liraglutide, lixisen-
atide also crosses the BBB into CNS, whereby it has been shown
to exert strong neurogenic effects in an AD rodent model (124,
141) (Figure 1), as well as to prevent Aβ-related impaired synap-
tic plasticity, hippocampal LTP, and spatial learning memory in a
PI3K/Akt/GSK-3β-mediated pathway (142). Despite such potent
brain protective effects, further in vivo and clinical research aiming
at the treatment of neurodegenerative diseases with lixisenatide are
needed. Regarding albiglutide, this molecule consists of two GLP-
1 (7–36) molecules connected to recombinant human albumin
(143), in which a single amino acid substitution (ala→ gly) ren-
ders it resistant to DPP-IV, with a half-life of ~5 days that allows
for a weekly dosing (144). Unfortunately, its size renders albiglu-
tide unable to cross the BBB (145), thereby rendering the potential
peripheral use of albiglutide against neurodegenerative disorders
somehow unfeasible and first requiring the development of effi-
cient CNS delivery strategies. Importantly, albiglutide’s adverse
effects include nausea, injection site reactions (47), and eventually
some degree of gastrointestinal intolerability (145), which must
be taken into account when prescribing this drug to patients with
gastrointestinal problems.
CONCLUSION
Type 2 diabetes patients often develop some form of demen-
tia (such as AD), whereas AD patients may also present hyper-
glycemia, hypercholesterolemia, and insulin signaling dysfunc-
tion (common features to T2D). Thus, it has been increasingly
suggested that several anti-T2D drugs may have a therapeu-
tic potential in dementia, with some of them already under
clinical analysis for that purpose. In fact, some of the above-
mentioned anti-diabetics were beneficial against some AD hall-
marks, e.g., Aβ plaque formation and tau hyperphosphorylation.
Some of them also promoted neurogenesis and cell prolifera-
tion, and reduced neuroinflammation and cell death. However,
despite so many promising preventive and/or treatment strate-
gies against human dementia, a precise knowledge on (1) the
underlying common mechanisms between T2D and AD, and
(2) the molecular determinants of such drugs’ effects, both
peripherally and centrally, with a special emphasis on T2D-
and/or AD-related damage, is urgently needed to unquestion-
ably consider that “what is good for T2D treatment is also good
for AD.”
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